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Abstract
The effect of mild chronic renal failure (CRF) induced by 4/6-nephrectomy (4/6NX) on central neuronal activations was
investigated by c-Fos immunohistochemistry staining and compared to sham-operated rats. In the 4/6 NX rats also the
effect of the angiotensin receptor blocker, losartan, and the central sympatholyticum moxonidine was studied for two
months. In serial brain sections Fos-immunoreactive neurons were localized and classified semiquantitatively. In 37 brain
areas/nuclei several neurons with different functional properties were strongly affected in 4/6NX. It elicited a moderate to
high Fos-activity in areas responsible for the monoaminergic innervation of the cerebral cortex, the limbic system, the
thalamus and hypothalamus (e.g. noradrenergic neurons of the locus coeruleus, serotonergic neurons in dorsal raphe,
histaminergic neurons in the tuberomamillary nucleus). Other monoaminergic cell groups (A5 noradrenaline, C1 adrenaline,
medullary raphe serotonin neurons) and neurons in the hypothalamic paraventricular nucleus (innervating the sympathetic
preganglionic neurons and affecting the peripheral sympathetic outflow) did not show Fos-activity. Stress- and pain-
sensitive cortical/subcortical areas, neurons in the limbic system, the hypothalamus and the circumventricular organs were
also affected by 4/6NX. Administration of losartan and more strongly moxonidine modulated most effects and particularly
inhibited Fos-activity in locus coeruleus neurons. In conclusion, 4/6NX elicits high activity in central sympathetic, stress- and
pain-related brain areas as well as in the limbic system, which can be ameliorated by losartan and particularly by
moxonidine. These changes indicate a high sensitivity of CNS in initial stages of CKD which could be causative in clinical
disturbances.
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Introduction
Patients with the most severe stage of chronic kidney disease
(stage 5 CKD) or on maintenance hemodialysis are afflicted by
remarkable cognitive deficits [1,2,3,4], enhanced perception of
pain [5,6], sleep disturbances including sleep apnea [6,7]
depression [8,9], and impaired quality of life [10]. Among the
pathogenic factors involved in the disturbances of the central
nervous system (CNS) enhanced blood levels of uremic neurotox-
ins (guanidino- and phenolic-compounds, indoxyl sulphate) [11],
neurotoxic advanced glycation end products (AGEs) [12,13,14],
homocysteine [15], asymmetric dimethylarginine (ADMA)
[15,16], pro-inflammatory cytokines and reactive oxygen species
(ROS), which are partly released from the damaged kidney
(‘‘distant renal effects‘‘) play a role [17,18,19]. Moreover, over-
activity of sympathetic nervous system (SNS) [20,21] contribute to
dysregulation of brain functions. In CKD rats, the concentrations
of norepinephrine in posterior hypothalamic nuclei and locus
coeruleus (LC) are enhanced [22]. The damaged kidneys releases
norepinephrine and angiotensin II [23]. Norepinephrine produc-
tion is further enhanced by accumulated ADMA [24] and reactive
oxygen species [25]. Rats with severe acute kidney injury display
markedly elevated neuronal c-fos and Fra-2 immunoreactivities in
the central biogenic amine cell groups, stress-sensitive forebrain
areas/nuclei, central autonomic and neuronal cell groups involved
in the regulation of fluid and electrolyte homeostasis [26].
Interestingly, symptoms of cognitive impairment, poor learning,
concentration deficits [27,28,29], enhanced perception of pain and
sleep disorders/sleep apnea [30,31,32] may occur even in mild to
moderate stages of CKD (GFR ,60 ml/min). Recent investiga-
tions revealed manifestation of cognitive dysfunction in albumin-
uric subjects even with a normal GFR [33]. Since albuminuria is a
marker of micro-vascular disease it is assumed that it indicates
endothelial dysfunction also in brain microvessels. Albuminuria
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may additionally be associated with accumulation of ADMA [34]
and oxidative stress [35].
The underlying pathomechanisms of CNS disturbances in mild
to moderate CKD are poorly understood and the potential
changes of neuronal activity in the CNS have not been analyzed.
Therefore, we investigated the brain activation pattern by Fos
after renal mass reduction employing 4/6-nephrectomy (4/6NX).
This model assures symmetry in renal afferents signaling to the
brain. Due to compensatory renal hypertrophy it is not associated
with a relevant rise of uremic solutes or severe hypertension at
least in early stages [36]. Therefore the potential direct/indirect
effects of damaged kidney on the brain can be studied.
Immunohistochemical detection of Fos-expression is a common
marker of neuronal activation in CNS [37,38]. The c-fos gene has
short expression time, but repeated or permanent chronic stimuli
may induce Fos expression persisting for days to weeks [39,40,41].
Long-term Fos-immunoreactivity could reflect the re-expression of
Fos in neurons that receive continuous input [42,43].
To study the therapeutic effects on central neuronal activation,
the 4/6NX rats were administered the angiotensin II type 1
receptor blocker (ARB) losartan [44,45,46], and the central
sympatholytic agent moxonidine, a mixed a2-adrenergic and
imidazoline receptor agonist [47] in the rostral ventrolateral
medulla of the brainstem [48]. Reduced central sympathetic
outflow and thereby lowered peripheral sympathetic tone result in
protective reno- and cardiovascular effects [48,49].
Methods
Animal Treatment
The investigation was conducted according to the guidelines for
studies using laboratory animals (86/609/EEC), after approval of
the protocol by the State Veterinary and Food Administration
(Bratislava, Slovakia). Male Wistar rats (Charles River, Budapest,
Hungary) weighing 284 g 620 g, were housed in rooms with
constant temperature and humidity, 12 h/12 h light/dark cycle,
with ad libitum access to drinking water and food (SP1, Horné
Dubové, Slovakia).
One week after acclimatization, 12 rats were subjected to
ablation of 2/3 of the renal parenchyma of the left kidney,
followed by a 2/3 nephrectomy of the contralateral kidney 14 days
thereafter (4/6NX) [50], both under i.p. ketamin/xylazin anes-
thesia. Sham (SHAM, n = 4) rats were operated in parallel. Five
days after the second surgery, the 4/6NX rats were randomized
into 3 groups (n = 4, each) receiving placebo (vehicle), an
angiotensin receptor blocker losartan (3 mg/kg body wt/d), or a
selective imidazoline receptor-1 agonist, moxonidine (2 mg/kg
body wt/d) in drinking water for 60 days. Previous studies showed
that these dosages exert renoprotective effects without a relevant
antihypertensive action [51,52]. Since moxonidine is poorly
soluble in water, solutions of both drugs were prepared by dilution
of the appropriate amount of the substance (adjusted weekly to
body weight) in 10 ml of 0.9% NaCl, pH = 4.6, which was added
to 990 ml of tap water. The vehicle contained the corresponding
amount of pH-adjusted NaCl. One week prior to sacrifice, heart
rate and blood pressure were recorded using tail plethysmography.
Five days before sacrifice, rats were placed into metabolic cages for
24-hours stool-free urine collection. At sacrifice, blood was
collected from the abdominal aorta. Then the rats were
cannulated through the left ventricle and right carotid artery,
while the brain was slowly perfused with chilled saline to remove
the blood from the vessels, and fixed with the chilled infusion of
4% paraformaldehyde. The kidneys were harvested and weighed.
Standard blood and urine chemistry parameters were measured
(Vitros 250 analyzer, J&J, Rochester, USA). Plasma concentration
of AGE-associated fluorescence [53], and of advanced oxidation
protein products (AOPPs) [54] were determined.
Statistical Analysis of Morphometric and Biochemical
Data
All values are expressed as mean 6 standard error. Statistical
significance among multiple groups was tested using the Kruskal-
Wallis test with post-hoc Mann-Whitney U-test (two-tailed, exact)
with Bonferroni correction. p,0.05 was considered significant.
SPSS v. 16 programs was employed.
Fos Immunostaining and Semi-quantitative Analysis of
the Data
Fos immunostaining was performed on coronal serial sections of
rat brains, as previously described [26]. More than 100 different
brain areas and nuclei have been checked under the microscope in
each animal (n = 16). In more than 50% of the investigated brain
areas, neuronal cells did not show any Fos-immunopositivity at the
moment of the decapitation. In total, 37 brain areas or nuclei were
found that contained Fos-positive neurons in various densities.
The percentage of Fos-immunopositive cells in the total cell
number of the investigated brain nuclei or areas were counted and
classified. According to the percentual rate of Fos-positive neurons
within a brain nuclei, grading 0 to 3 was used, as follows: 1) high
Fos expression (grade: 3.00) = more than the half of the cells in the
investigated brain areas or nuclei showed Fos-positivity; 2)
moderate Fos-expression (grade: 2.00) = the percentage of the
Fos-positive cells was between 25 and 50% of the total cell
number; 3) low Fos expression (grade: 1.00) = less than the 25
percent of the cells were immunostained for Fos; 4) no Fos
expression = grade 0. In the tables, the average values from 3 or 4
animals are given. According to the functional role of the cell
groups and brain areas, the Fos-immunoreactive cells were
classified into 6 groups: 1) biogenic amine-expressing cell groups,
2) brain nuclei involved in the central regulation of the salt and
electrolyte homeostasis, 3) stress-related hypothalamic areas and
nuclei, 4) pain-related brain areas and nuclei, 5) limbic brain areas
and nuclei, 6) other brain areas and nuclei.
Results
At sacrifice, the untreated and treated groups did not differ
significantly in body weight or kidney-to-body-weight ratio
(Table 1). The placebo-administered 4/6NX rats displayed a
higher systolic blood pressure (149614) in comparison to the
sham-operated control rats (12869) (+16%, n.s., Table 1). The
high standard deviation in the 4/6 NX rats is a consequence of
one outlier with blood pressure of 174 mm Hg. If this rat is
excluded, the mean blood pressure of this group would drop to
13467 Hg. The placebo-administered 4/6NX rats also displayed
a lower creatinine clearance (226%, n.s., Table 1) compared to
sham-operated animals. Treatment with losartan or moxonidine
did not affect these parameters significantly (Table 1).
4/6NX placebo-treated rats revealed a 3.4-fold higher protein-
uria (p,0.05) compared to their sham-operated counterparts
(Table 1). This was reduced by losartan (270%, p,0.05), while
the moxonidine-induced amelioration (250%) did not reach
significance. Mean food intake was similar among the groups (data
not shown), thus proteinuria was not affected by different protein-
caloric intake.
Plasma AGE-associated fluorescence was higher (+43%,
p,0.05), while that of advanced oxidation protein products
Neural Activation in 4/6 Nephrectomized Rats
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(AOPPs) showed a trend to elevated levels (+29%, n.s.) in the 4/
6NX rats (Table 1). Administration of moxonidine, but not
losartan lowered the AGE levels (220%, p,0.05), while losartan,
but not moxonidine, ameliorated the accumulation of AOPPs
(260%, p,0.05). Plasma levels of albumin were within the normal
range in all groups and were not affected by the treatments (data
not shown).
Fos-activation in the Brain of Sham-operated and 4/6NX
Rats
In general 4/6NX rats established increased Fos-activation
throughout the brain except for few brain nuclei, where no
alteration or even decreased activations were observed.
Actions on central monoaminergic neurons. Slight to
moderate Fos-activity was detected in some of the monoaminergic
neurons in the lower brainstem of sham-operated rats. 4/6NX
resulted in further activation in the major cell groups such as locus
coeruleus (LC), dorsal raphe and tuberomamillary nuclei, while
neurons in several other (smaller) groups remained silent (Fig. 1,
Table 2).
Noradrenaline cell group, fairly high Fos-activity was seen in LC
neurons of 4/6NX rats, while the forebrain projecting caudal
ventrolateral (A1 cell group) and dorsomedial (A2 cell group)
noradrenaline neurons did not show altered activities. Neurons
projecting to the sympathetic preganglionic neurons in the spinal
cord (A5 noradrenaline cell group) showed even less activity in 4/
6NX rats than in sham-operated animals.
Adrenaline neurons in the medulla oblongata (C1-C3 cell groups),
or dopaminergic neurons in substantia nigra/ventral tegmental area
and in diencephalon showed minor or no activation in 4/6NX rats
(Table 2).
Actions on brain nuclei involved in the central regulation
of the fluid and electrolyte homeostasis and on brain areas
where no blood-brain barrier exists. In sham-operated rats
the Fos-activation was moderate to high in the vasopressin-
expressing magnocellular neurons of the supraoptic and para-
ventricular hypothalamic nuclei (Table 2) which was reduced by
4/6NX (Fig. 1). Elevation in Fos-activity was observed in the
anterior (preoptic) part of the hypothalamus, namely in the
median preoptic antrioventral third ventricle region (AV3V
region) and in the organum vasculosum laminae terminalis
(OVLT) of the 4/6NX rats (Table 2). 4/6NX did not elicit Fos-
activation in the other blood-brain barrier-free brain areas
(subfornical organ-SFO-, area postrema).
Actions on ‘‘stress-related’’ hypothalamic areas and
nuclei. Neurons in all ‘‘stress-sensitive’’ hypothalamic nuclei
(parvocellular paraventricular, supramamillary, dorsomedial) and
in the lateral hypothalamic area showed signs of activation in
sham-operated rats with further Fos-activation in 4/6NX animals
(Fig. 1, Table 2). Elevated Fos-activity was also found in the lateral
septal nucleus in 4/6NX rats (Fig. 1), nevertheless, neurons in the
central amygdaloid nucleus failed to show any sign of Fos-
expression either in sham-operated or 4/6NX rats (Table 2).
Actions on pain-related brain areas. Strong Fos-activation
was detected both in somato- and viscera-sensory (insular) cortical
areas in sham-operated, and stronger in 4/6NX animals. In
contrast, subcortical neurons in pain-related medullary viscero-
sensory nucleus (the nucleus of the solitary tract - NTS) or in the
periaqueductal central gray (PAG) did not express Fos in 4/6NX
rats (Fig. 1, Table 2).
Actions on limbic cortical and subcortical
areas. Neurons in the major limbic cortical areas (prefrontal,
piriform, anterior cingulate cortices) were strongly activated in
both sham-operated and 4/6NX animals (Fig. 1, Table 2). In the
hippocampus, no Fos-activation was seen either in the CA1-CA3
regions or in the dentate gyrus, while slight activity was observed
in the ventral subiculum of 4/6NX rats. Strong Fos-activation was
seen in the olfactory tubercle (Fig. 1).
Fos Activation in the Brain after Losartan and Moxonidine
Treatments in 4/6NX Rats
In general, losartan or moxonidine treatments altered Fos-
expression throughout the CNS and showed many similarities.
Actions on central monoaminergic neurons. Losartan and
moxonidine markedly reduced the enhanced Fos-activation in the
LC of the 4/6NX rats (Fig. 2 and 3, Table 2). In addition,
moxonidine lowered the moderate Fos-activation in noradrenaline
(A5) and adrenaline (C1) neurons in the ventrolateral medulla that
project to the spinal sympathetic preganglionic neurons (Fig. 3). It
also reduced Fos-activity in medullary raphe neurons that project
to the spinal cord of 4/6NX rats, whereas the forebrain projecting
serotonin neurons in the dorsal raphe nucleus were not activated
(Table 2). The fairly high numbers of Fos-positive cells in the
histaminergic tuberomamillary nucleus were reduced by losartan
(Table 2).
Table 1. Characteristics of sham-operated and 4/6-nephrectomized (4/6NX) rats at sacrifice.
Sham-operated 4/6NX
Placebo (n = 4) Placebo (n = 4) Losartan (n = 4) Moxonidine (n = 4) p (K-W)
Body weight (g) 494645 495613 438641 446621 NS
Kidney/body weight (mg/g) 6.060.1 6.460.5 5.860.3 5.860.3 NS
Blood pressure (mm Hg) 12869 149614 13165 12962 NS
ClCreatinine (ml/min/1g kidney) 0.8660.13 0.6860.03 0.8660.09 0.7460.09 NS
Proteinuria (mg/mmol crea) 175630 6036205+ 174614* 307654 0.024
Serum AGE/Albumin (AU/g) 4.460.3 6.360.7+ 6.160.1 5.160.1* 0.048
Serum AOPPs/Albumin (mmol/g) 4.560.5 5.861.3 2.460.7* 5.560.2 0.039
Cl: clearance; AGE: advanced glycation end products-associated fluorescence of plasma; AU: arbitrary units; AOPPs: plasma advanced oxidation protein products; K-W:
Kruskal-Wallis test;
+: p,0.05 vs. SHAM-PLAC;
*: p,0.05 vs. 4/6NX-PLAC (Exact 2-sided Man-Whitney U-test with Bonferonni correction).
doi:10.1371/journal.pone.0066543.t001
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Actions on brain nuclei involved in the central regulation
of the fluid and electrolyte homeostasis and on brain areas
where no blood-brain barrier exists. The moderate Fos-
activity in supraoptic and magnocellular paraventricular nuclei
was slightly elevated (Table 2). Moxonidine had minor effect on
supraoptic nuclei, but markedly increased Fos-activity in para-
ventricular nucleus (Table 2, Fig. 3). Losartan did not modulate
Fos-activity in OLVT (Fig. 2, Table 2), but monoxidine reduced
the activity of these neurons (Table 2). It is hard to explain the
excitatory action of losartan on the SFO. Both drugs failed to elicit
any such effect in area postrema (Table 2).
Actions on ‘‘stress-related’’ hypothalamic areas and
nuclei. In 4/6NX animals the number of Fos-positive neurons
in the stress-related nuclei of the hypothalamus was much lower
after losartan or moxonidine treatment than that of placebo-
treated rats (Table 2). Both drugs failed to act on central
amygdaloid neurons.
Actions on pain-related brain areas. In 4/6NX rats, both
drugs strongly reduced the number of Fos-positive neurons in the
somatosensory cortex. They had opposite effects on the viscero-
sensory cortex (insula): losartan further activated Fos, while
moxonidine reduced it (Table 2, Fig. 2 and 3).
Actions on limbic cortical and subcortical areas. The 4/
6NX-induced high number of Fos-positive cells in the investigated
limbic cortical areas and the olfactory tubercle were diminished
after moxonidine treatment (Fig. 3, Table 2). The response to
losartan treatment was ambivalent. Some areas like the prefrontal
cortex, showed further increase in the number of Fos-positive cells,
while their number decreased in the anterior cingulate cortex and
Figure 1. Sagittal (A) and coronal (B and C) drawings of the rat brain with the topography of brain nuclei and areas where neurons
responded to experimental chronic renal failure (4/6 nephrectomy) with moderate to high expressions of Fos as compared to sham-
operated animals. The rostro-caudal levels of the coronal sections are indicated on Fig. A). Dark blue=highly, light blue =moderately elevated Fos
activation, red = highly, light red=moderately depleted Fos activation. (For the level of numerical changes see Table 2.) Abbreviations: CA – anterior
commissure, CC – corpus callosum, F – fornix. Brain nuclei and areas: 1 – locus coeruleus, 2 – A1 noradrenaline cell group, 3 – A5 noradrenaline cell
group, 4 – C1 adrenaline cell group, 5 – dorsal raphe nucleus, 6 – medullary raphe nuclei, 7 – supraoptic nucleus, 8 – hypothalamic paraventricular
nucleus (magnocellular portion), 9 – preoptic AV3V area, 10 – organum vasculosum laminae terminalis (OVLT), 11 – subfornical organ, 12 – area
postrema, 13 – hypothalamic paraventricular nucleus (parvocellular portion), 14 – hypothalamic dorsomedial nucleus, 15 – supramamillary nucleus,
16 – lateral hypothalamic area, 17 – lateral septum, 18 – central amygdala nucleus, 19 – somatosensory cortex, 20 – viscerosensory cortex (insula), 21
– nucleus of the solitary tract, 22 – periaqueductal gray matter (PAG), 23 – prefrontal cortex, 24 – piriform cortex, 25 – anterior cingulate cortex, 26 –
hippocampus (CA1-3), 27 – subiculum, 28 – olfactory tubercle, 29 – substantia nigra/VTA dopamine neurons.
doi:10.1371/journal.pone.0066543.g001
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in the subiculum (Table 2, Fig. 2). Both drugs did not modulate
Fos-activity in the hippocampus (Table 2).
Discussion
Here, we demonstrate for the first time that 4/6NX elicits
marked alterations of Fos-activation in different brain areas/
nuclei. Due to compensatory renal hypertrophy the GFR was only
mildly reduced, but proteinuria and circulating AGEs were
elevated. The higher blood pressure in the 4/6 NX rats was in
particular due to one outlier animal with hypertension, while the
blood pressure in other animals of the group was not elevated.
Therefore, it seems unlikely that the observed alterations in
neuronal activation are particularly induced by hypertension.
However, an ultimate statement about the potential role of
hypertension on central neuronal activity requires an additional
Table 2. Fos expression in various brain areas after 4/6NX and its treatment with losartan and moxonidine.
Sham-operated
rats (Grade) 4/6NX rats
Placebo Losartan Moxonidine
Grade D vs. Sh-P D vs. 4/6NX-P D vs. Sh-P D vs. 4/6NX-P D vs. Sh-P
Biogenic amine cell groups
locus coeruleus 0.75 2.00 +1.25 21.25 0 21.75 20.50
A1 NA cell group 0 0 0 0 0 0 0
A5 NA cell group 1.00 0.25 20.75 0 20.75 0 20.75
C1 A cell group 1.00 1.00 0 0 0 0 0
substantia nigra/VTA 0 0.25 +0.25 0 +0.25 0 +0.25
dorsal raphe nucleus 0.25 0.75 +0.50 20.50 0 0 +0.50
medullary raphe nuclei 1.00 1.00 0 0 0 20.50 20.50
tuberomamillary nucleus 2.00 2.50 +0.50 20.75 20.25 20.50 0
Salt and water homeostasis
supraoptic nucleus 1.50 1.00 20.50 0 20.50 0 20.50
magnocellular PVN 1.00 0.25 20.75 0 20.75 +1.50 20.75
preoptic AV3V area 0.50 1.00 +0.50 0 +0.50 0 +0.50
Blood-brain barrier free
OVLT 1.00 1.50 +0.50 0 +0.50 20.50 0
subfornical organ 0 0 0 +0.75 +0.75 0 0
area postrema 0 0 0 0 0 0 0
Stress-related brain areas
parvocellular PVN 1.75 1.75 0 0 0 20.50 20.50
dorsomedial nucleus 1.25 2.00 +0.75 0 +0.75 20.50 +0.25
supramamillary nucleus 1.50 2.25 +0.75 20.50 +0.25 21.00 20.25
lateral hypothalamic area 1.25 1.50 +0.25 0 +0.25 21.00 20.75
lateral septal nucleus 2.00 2.25 +0.25 21.25 21.00 20.50 20.25
central amygdala 0 0 0 0 0 0 0
Pain-related brain areas
somatosensory cortex 1.50 2.50 +1.00 20.75 +0.25 21.50 20.50
viscerosensory cortex 1.25 1.50 +0.25 +0.25 +0.50 20.50 20.25
nucl. of the solitary tract 0 0 0 0 0 0 0
PAG (central gray), dorsolat. 0.50 0.50 0 0 0 0 0
Limbic brain areas
prefrontal cortex 1.00 2.00 +1.00 +0.50 +1.50 21.25 20.25
piriform cortex 2.25 2.50 +0.25 0 +0.25 21.25 21.00
anterior cingulate cortex 0.50 1.50 +1.00 20.50 +0.50 21.25 20.25
Hippocampus (CAs+DG) 0.50 0.75 +0.25 0 +0.25 0 +0.25
subiculum 0.25 1.00 +0.75 20.75 0 20.75 0
olfactory tubercle 1.00 2.00 +1.00 0 +1.00 21.00 0
P: placebo; Grade: grading of c-fos expression (as given in Methods section); D: change; Sh: sham-operated; NA: noradrenaline; A: adrenaline; VTA: ventral tegmental
area; PVN: paraventricular nucleus; OVLT: organum vasculosum laminae terminalis; PAG: periaqueductal gray matter; dorsolat.: dorsolateral; CAs: anterior commissure;
DG: dentate gyrus.
doi:10.1371/journal.pone.0066543.t002
Neural Activation in 4/6 Nephrectomized Rats
PLOS ONE | www.plosone.org 5 June 2013 | Volume 8 | Issue 6 | e66543
study employing hypertensive/normotensive animals with or
without 4/6NX.
Renal function of the 4/6NX rats corresponded clinically to
CKD stage 2–3a. This stage in humans may be associated with an
enhanced prevalence of pain perception and sleep disturbances
[6,31]. In addition, in humans in the presence of higher levels of
albuminuria/proteinuria a cognitive decline may occur even with
preserved GFR [33,55].
As a sign of central sympathetic overactivity, the 4/6NX rats
displayed a moderate to high Fos-activity in the neurons of LC,
which project to the forebrain and innervate the cerebral cortex,
the limbic system, the thalamus and the hypothalamus. LC is
involved in many functions such as arousal, attention and stress.
However, its prolonged activation could result in a disorganized
and unfocused behavior [56]. No alteration in Fos-activity was
observed in the A5 noradrenaline and C1 adrenaline cell groups,
as well as in parvocellular neurons in hypothalamic paraven-
tricular nucleus, that innervate sympathetic preganglionic neurons
in spinal cord and affect peripheral sympathetic outflow. In
patients with CKD peripheral sympathetic overactivity is a
prevalent disturbance. Its severity is inversely related to eGFR
and can be observed even in moderate CKD [21,24,57,58,59,60].
The dorsal raphe serotonin-expressing neurons, which provide a
significant proportion of the serotonin innervations to the
forebrain, showed a moderate activation in the 4/6NX rats. In
humans, serotonin pathways are namely involved in mood,
memory processing, sleep, cognition and satiety. The observed
Fos-activation in the prefrontal and anterior cingulate cortex may
be implicated in depressive symptoms and sleep disorders
occurring in mild to moderate CKD [31,32,61]. In advanced
CKD in rats and humans the high brain serotonin levels could
contribute to uremic anorexia [62,63,64].
Our data suggest that histamine-expressing neurons in the
hypothalamic tuberomamillary nucleus (the major if not the sole
site of histamine synthesis in the brain) become activated in mild
CKD. This system has a key position in basic body functions such
as sleep/waking cycle, learning and synaptic plasticity [65]. In
advanced CKD in rats and patients the high brain histamine
content may contribute to an increased vascular permeability,
brain edema and disruption of blood-brain barrier [66,67].
Figure 2. Sagittal (A) and coronal (B and C) drawings of the rat brain with the topography of brain nuclei and areas where
nephrectomized rats responded with losartan treatment with moderate to high expressions of Fos as compared to placebo-treated
nephrectomized animals. The rostro-caudal levels of the coronal sections are indicated on Fig. A). Dark blue=highly, light blue =moderately
elevated Fos activation, red = highly, light red=moderately depleted Fos activation. (For the level of numerical changes see Table 2.) Abbreviations and
numbers: see Fig. 1.
doi:10.1371/journal.pone.0066543.g002
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Our data suggest that renal mass ablation elicits also changes in
the regulation of fluid and salt homeostasis. Fos-activity of the
vasopressin-expressing supraoptic and magnocellular paraventri-
cular neurons is reduced, while neurons in the preoptic AV3V
area and the OVLT, where the majority of brain atrial natriuretic
peptide (ANP)-expressing cells are located [68], showed moderate
Fos-activity. Accordingly, in earlier studies rats with advanced
CKD presented elevated levels of ANP in the OVLT and the
AV3V area [69].
In stress-related brain areas/nuclei a high Fos-activation was
observed in the dorsomedial and supramamillary hypothalamic
nuclei, but unexpectedly no changes occurred in parvocellular
PVN and in central amygdala. In CKD patients with an eGFR
#60 ml/min an exaggerated hemodynamic response to mental
stress has been observed [70].
Among the pain-related brain areas Fos-expression was
upregulated in the somatosensory and viscerosensory cortex,
indicating central sensitization to noxious factors including
enhanced stress-induced hyperalgesia in animal models [71]. 4/
6NX failed to elicit Fos-activation in NTS and PAG.
In the limbic brain areas Fos-activity was augmented in all six
investigated areas/nuclei. The prefrontal cortex is considered to be
implicated in cognitive control and ‘‘the ability to orchestrate
thoughts and actions in accordance to internal goals’’ [72]. In
humans neurons of anterior cingulate cortex are involved in
regulation of blood pressure, heart rate and baroreflex sensitivity
[73] as well as in empathy and emotion [74].
A marked expression of c-fos was found in the olfactory bulb of
4/6NX rats. In humans disturbances in taste and smell function
are uncommon in mild CKD but may appear in moderate to
severe CKD [75,76,77] and may contribute to appetite loss
[77,78,79].
The observed changes in Fos-activity in various brain areas do
not allow an extrapolation of these findings on behavior, sleep
disturbances or pain perception. There is a need to perform an
appropriate battery of available behavioral tests in rats subjected to
4/6 NX as well as sham-operated rats, which could bring an
insight on the association of the observed changes in brain
signaling with those of behavior.
Figure 3. Sagittal (A) and coronal (B and C) drawings of the rat brain with the topography of brain nuclei and areas where neurons
in nephrectomized rats responded to moxodinine treatment with moderate to high expressions of Fos as compared to placebo-treated
nephrectomized animals. The rostro-caudal levels of the coronal sections are indicated on Fig. A). Dark blue=highly, light blue =moderately
elevated Fos activation, red = highly, light red=moderately depleted Fos activation. (For the level of numerical changes see Table 2.) Abbreviations and
numbers: see Fig. 1.
doi:10.1371/journal.pone.0066543.g003
Neural Activation in 4/6 Nephrectomized Rats
PLOS ONE | www.plosone.org 7 June 2013 | Volume 8 | Issue 6 | e66543
In the 4/6NX rats administration of moxonidine and losartan
exerted marked effects on Fos-activity. A subantihypertensive dose
of moxonidine caused a substantial reduction of Fos-activity in the
LC and all investigated forebrain areas/nuclei innervated by LC
neurons. This corresponds to earlier studies in 5/6NX rats, where
moxonidine reduced the central sympathetic overactivity [20].
The effects of moxonidine were particularly striking in all stress-
related areas/nuclei. Lowering of Fos-activity was very pro-
nounced in the dorsomedial nucleus, the supramamillary nucleus
and in the hypothalamic area. As expected, moxonidine also
decreased Fos-activity in pain-related areas such as somato- and
viscerosensory cortex. These findings fit to clinical observations in
humans that agonists of a-2-adreno-receptors (which mediate
analgesia) are very effective in the treatment of pain [80].
Moxonidine also reduced the enhanced Fos-activity in 5 of the 6
investigated limbic brain areas: prefrontal, piriform cortex,
anterior cingulate cortex, the subiculum and olfactory tubercle.
In the areas/nuclei involved in fluid and salt homeostasis
moxonidine decreased Fos-activity in supraoptic and magnocellu-
lar PVN, where the hormones oxytocin and vasopressin are
formed. Fos-activity in the preoptic AV3V region was increased as
compared to sham-operated rats. Acute moxonidine administra-
tion enhances the ANP formation resulting in diuresis and
natriuresis in rats [81].
Losartan, which passes through the blood-brain barrier [60]
and ameliorates central sympathetic activity [21,55,82,83] reduced
Fos-activity in particular in LC and in the stress-related brain areas
such as supramamillary and lateral septal nuclei. In pain-related
areas losartan lowered Fos-activity only in the somatosensory
cortex, while the activity in the viscerosensory cortex even
increased. The latter effect fit to the clinical observation of a
hyperalgesic action of losartan as well as of the ACE-inhibitor
enalapril in the treatment of hypertensive patients [84]. Also in the
limbic brain areas the response to losartan was different to that of
moxonidine: elevation of Fos in prefrontal cortex and lowering in
anterior cingulated cortex and subiculum. Among the nuclei
involved in fluid and salt homeostasis, losartan enhanced the Fos-
activity in SFO which is involved in blood volume homeostasis.
Which mechanisms underlie the altered Fos-activation pattern
in mild CKD? Recent cross-sectional and longitudinal studies in
humans [85] documented that albuminuria may be associated
with cognitive decline [86]. In the PREVEND study particularly
young subjects with albuminuria presented a poorer cognitive
function [33]. In other studies, it has been shown that albuminuria
is associated with endothelial dysfunction [87] and cerebral small
vessel disease [88]. Therefore it is conceivable that the cognitive
impairment may be a consequence of sub-clinical cerebral micro-
vessel disease. Extravasation of proteins due to microvascular
disease could contribute to brain damage as demonstrated by
white matter hyperintensities with a perivascular distribution
[89,90]. In line with these findings administration of centrally
acting ACE-inhibitors in older adults concurrently ameliorated not
only proteinuria but also protected against cognitive decline [91].
Correspondingly in our study administration of losartan and
moxonidine was associated with a decline in proteinuria.
A possible link between albuminuria, endothelial dysfunction
and cognitive decline in humans could be an enhanced formation
of ADMA [92]. Remarkably, serum ADMA levels are directly
related to albuminuria and may be its causal contributor [24].
ADMA attenuates NO-dependent vasodilation, enhances oxida-
tive stress, triggers sympathetic over-activity and promote athero-
sclerosis in rats [93]. In healthy subjects administration of
subpressor doses of ADMA decreased cerebral perfusion and
increased vascular stiffness [94]. In the Framingham offspring
study higher plasma ADMA levels were associated with MRI
markers of vascular brain injury [95]. Therefore, ADMA may be
involved in the pathogenesis of cerebrovascular disease and the
concomitant cognitive decline in CKD [94]. ADMA also promotes
progression of non-diabetic kidney diseases in humans [16]. The
potential involvement of ADMA in the above mentioned
conditions is supported by the observation that the ACE-inhibitor,
ramipril, lowers proteinuria and circulating ADMA in patients
with diabetic nephropathy [96]. We hypothesize that in our study
the losartan- and moxonidine-induced modulation of neural
activation in the 4/6NX rats is in part a consequence of an
improved endothelial dysfunction as a consequence of decreased
ADMA levels. Moreover, ameliorated Fos-activity are explained
by specific effects of losartan and particularly moxonidine on the
central sympathetic nervous system. The strength of the current
study is the first description of numerous central disturbances in
the early stage of CKD. Its limitation is the small size of the animal
groups.
In conclusion, 4/6 ablation of renal mass alters the activation of
neurons in numerous brain areas/nuclei with different functional
properties. Especially, the central sympathetic nervous system such
as the LC, the limbic areas as well as stress- and pain-related areas
are affected. It is conceivable that these activations may be
causative or predictive of numerous clinical complications.
Treatment with the ARB losartan or the central sympatholytic
agent moxonidine ameliorates many of the observed central
alterations.
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Tex. Des. Zuzana Šebeková from Academy of Fine Arts and Design,
Bratislava, Slovakia in acquisition of the brains.
Author Contributions
Conceived and designed the experiments: MP KŠ AH. Performed the
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